BRAF and melanoma: In NSCLC, 2–4% of patients possess BRAF V600 mutations.100 Although BRAF inhibitors (vemurafenib and dabrafenib) were originally developed for the treatment of melanoma, recent clinical trials with the inhibitors showed potential in BRAF V600 mutant NSCLC patients (Table 3).